Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “First or Second Line Therapy”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableUnknownNCT04443036
What this trial is testing

Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma

Who this might be right for
Gastric Carcinoma
China Medical University, China 44
Testing effectiveness (Phase 2)Study completedNCT01946477
What this trial is testing

Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting

Who this might be right for
Multiple Myeloma
Celgene 186
Testing effectiveness (Phase 2)Study completedNCT00110045
What this trial is testing

Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant

Who this might be right for
Cancer
European Organisation for Research and Treatment of Cancer - EORTC 171
Testing effectiveness (Phase 2)Study completedNCT02610140
What this trial is testing

Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)

Who this might be right for
Mesothelioma
Bayer 248
Not applicableUnknownNCT03802318
What this trial is testing

Daily Four Times or Two Times Usage of PPI and Amoxicillin for the First or Second Line H. Pylori Eradication

Who this might be right for
Helicobacter Pylori InfectionHelicobacter GastritisHelicobacter-Associated Pyloric Ulcer
Chang Gung Memorial Hospital 530
Testing effectiveness (Phase 2)Looking for participantsNCT06783348
What this trial is testing

Radiopharmaceutical Treatment of Advanced Kidney Cancer

Who this might be right for
Metastatic Clear Cell Renal Cell Carcinoma
European Organisation for Research and Treatment of Cancer - EORTC 48
Testing effectiveness (Phase 2)Ended earlyNCT00709618
What this trial is testing

Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects

Who this might be right for
Neoplasms, Breast
GlaxoSmithKline 44
Testing effectiveness (Phase 2)Ended earlyNCT01120171
What this trial is testing

Myocet Plus Endoxan for Older Patients With Breast Cancer

Who this might be right for
Breast Cancer
Hellenic Oncology Research Group 64
Testing effectiveness (Phase 2)Looking for participantsNCT06841055
What this trial is testing

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

Who this might be right for
Non-small Cell Lung Cancer
BioNTech SE 60
Testing effectiveness (Phase 2)Study completedNCT01111604
What this trial is testing

Ramucirumab or Icrucumab in Colorectal Cancer

Who this might be right for
Colon CancerRectal Cancer
Eli Lilly and Company 158
Not applicableUnknownNCT02155426
What this trial is testing

Prognostic and Dynamic Change of CTC Enumeration in Advanced NSCLC With Chemotherapy and Targeted Therapy

Who this might be right for
Non Small Cell Lung Cancer
Sun Yat-sen University 1,200
Not applicableStudy completedNCT05303740
What this trial is testing

Anlotinib Retrospective Study for Esophageal Cancer

Who this might be right for
Esophageal Neoplasms
Feng Wang 300
Not applicableEnded earlyNCT07000344
What this trial is testing

Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor

Who this might be right for
Ovarian Cancer
Peking Union Medical College Hospital 5
Post-approval studies (Phase 4)Study completedNCT02208843
What this trial is testing

Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 60
Testing effectiveness (Phase 2)Study completedNCT00004925
What this trial is testing

Liposomal Doxorubicin and Trastuzumab in Treating Women With Locally Advanced, Inflammatory, or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)Looking for participantsNCT06667076
What this trial is testing

Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 480
Testing effectiveness (Phase 2)Study completedNCT01530334
What this trial is testing

Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment

Who this might be right for
Lung Cancer
AstraZeneca 61
Testing effectiveness (Phase 2)Active Not RecruitingNCT06413745
What this trial is testing

Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer

Who this might be right for
HER2 Expression / Amplification in Patients With Biliary Tract Cancer
Jiangsu HengRui Medicine Co., Ltd. 59
Not applicableStudy completedNCT01955681
What this trial is testing

A Retrospective, Non-interventional, Multicenter, Observational Chart Review Study to Explore the Clinical Benefits of Retreatment With TKI in the Real World.

Who this might be right for
Locally Advanced or Metastatic EGFR Mutated NSCLC.
AstraZeneca 200
Testing effectiveness (Phase 2)Study completedNCT00312728
What this trial is testing

Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)

Who this might be right for
Non-Small Cell Lung CancerBrain Neoplasms
Genentech, Inc. 115
Next Page